News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

OSI Pharmaceuticals, Inc. (OSIP) Announces That Tarceva(R) Received Positive Opinion From Health Authorities In European Union For The Treatment Of Patients With Pancreatic Cancer



12/15/2006 9:25:54 AM

MELVILLE, N.Y.--(BUSINESS WIRE)--OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) and Roche, its international partner for Tarceva® (erlotinib), announced today that the European Committee for Medicinal Products for Human Use (CHMP), has issued a positive opinion recommending approval of once-daily Tarceva in combination with gemcitabine as first-line therapy for metastatic pancreatic cancer. This recommendation follows a request from Roche for a re-examination of the data supporting the filing for Tarceva in this indication. A final decision is expected from the European Commission within 45 days.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES